Merck

Merck
Share

Merck

 •  June 22

Call for health systems to join initiatives to improve care for specific patient populations
Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Premier Inc. (NASDAQ: PINC), a leading health care improvement company, have expanded their efforts to co-develop and test solutions to help improve patient care and wellness while...

Merck

 •  June 12

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today provided an update on two combination studies of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in the blood cancer multiple myeloma. Merck has accepted the external Data Monitoring Committee recommendation to pause new enrollment on KEYNOTE-183 and KEYNOTE-185,...

Merck

 •  June 5

Longer-Term Findings to Be Presented at 2017 ASCO Annual Meeting
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced updated overall survival (OS) findings from KEYNOTE-024, the phase 3 study evaluating KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, as a monotherapy compared to platinum-containing...

Merck

 •  June 3

Updated Phase 1/2 data from ECHO-202 investigating the combination of IDO1 enzyme inhibition and anti-PD-1 therapy in patients with advanced NSCLC, regardless of PD-L1 status, presented at 2017 ASCO Annual Meeting
Incyte Corporation (Nasdaq:INCY) and Merck (NYSD:MRK), known as MSD outside the United States and Canada, today announced updated data...

Merck

 •  June 3

First-Time Findings from KEYNOTE-164 and KEYNOTE-158, to Be Presented at ASCO, Further Support the Utility of MSI-H and dMMR as Predictive Biomarkers for Tumor-Agnostic Treatment Approach with KEYTRUDA
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of findings from KEYNOTE-164 and...

Merck

 •  June 2

Findings Show Durable Responses with KEYTRUDA after Treatment Concluded: 91 Percent of Patients Who Discontinued Treatment at Two Years Were Alive Without Progression of Disease after a Median Follow-Up of Nearly 10 Months
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced updated longer-term overall survival (OS)...

Merck

 •  May 30

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved ISENTRESS® HD, a new 1200 mg once-daily dose of the company’s integrase inhibitor, ISENTRESS® (raltegravir), to be administered orally as two 600 mg film-coated...

Merck

 •  May 25

KEYTRUDA Now Approved for MSI-H or dMMR Patients Whose Disease Has Progressed Following Prior Treatment and Who Have No Satisfactory Alternative Treatment Options, Which Includes Patients with Colorectal Cancer That Has Progressed Following Treatment with Fluoropyrimidine, Oxaliplatin, and Irinotecan With this Unique Indication, KEYTRUDA is the...

Merck

 •  May 23

KEYTRUDA Now Approved for Patients with MSI-H or Mismatch Repair Deficient Solid Tumors That Have Progressed Following Prior Treatment and Who Have No Satisfactory Alternative Treatment Options, Which Includes MSI-H or Mismatch Repair Deficient Colorectal Cancer That Has Progressed Following Treatment with a Fluoropyrimidine, Oxaliplatin, and...

Merck

 •  May 19

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of ISENTRESS® (raltegravir) 600 mg film-coated tablets, in combination with...